Alvotech - Ordinary Shares (ALVO)
11.20
+0.39 (3.61%)
Alvotech is a biotechnology company focused on the development and commercialization of high-quality biosimilar medicines
The company aims to provide affordable alternatives to branded biologic drugs, addressing the growing demand for cost-effective therapeutic options in various therapeutic areas. Alvotech leverages its proprietary technology platform to produce biosimilars that can offer similar safety and efficacy profiles to their reference products. Through strategic partnerships and a commitment to innovation, Alvotech strives to enhance patient access to vital medications on a global scale.

Via Benzinga · January 28, 2025

Via Benzinga · January 17, 2025

Via Benzinga · January 17, 2025

ALVO stock results show that Alvotech missed on revenue for the second quarter of 2024.
Via InvestorPlace · August 15, 2024

Alvotech just reported results for the fourth quarter of 2023.
Via InvestorPlace · March 20, 2024

Via Benzinga · January 15, 2025

UnitedHealth will remove AbbVie's Humira from its preferred drug lists by 2025, opting for lower-cost biosimilars like Amgen's Amjevita, in a move aimed at cutting prescription costs.
Via Benzinga · September 11, 2024

Via Benzinga · August 20, 2024

ALVO stock results show that Alvotech missed analyst estimates for earnings per share the first quarter of 2024.
Via InvestorPlace · May 21, 2024

It’s a rather quiet session on Tuesday, with major U.S. averages trading around the flatline at midday trading in New York.
Via Benzinga · May 21, 2024

Via Benzinga · April 19, 2024

U.S. stocks were lower, with the Dow Jones index falling around 100 points on Monday.
Via Benzinga · March 25, 2024

Companies Reporting Before The Bell • UP Fintech Holding (NASDAQTIGR) is expected to report quarterly earnings at $0.07 per share on revenue of $207.00 million.
Via Benzinga · March 20, 2024

Teva Pharmaceutical stock is rising higher on Monday after partner company Alvotech got approval from the FDA for a Humira biosimilar.
Via InvestorPlace · February 26, 2024

FDA-approved Simlandi (adalimumab-ryvk): a high-concentration biosimilar to Humira for rheumatoid arthritis, psoriasis, and more.
Via Benzinga · February 26, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via Benzinga · January 29, 2024

Via Benzinga · January 19, 2024

Companies Reporting Before The Bell • Elbit Systems (NASDAQESLT) is projected to report quarterly earnings at $1.70 per share on revenue of $1.45 billion.
Via Benzinga · November 28, 2023

Via Benzinga · October 20, 2023

Via Benzinga · September 21, 2023

Companies Reporting Before The Bell • Gaotu Techedu (NYSEGOTU) is expected to report earnings for its second quarter.
Via Benzinga · August 30, 2023